A61K 9/1641
Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
Official title: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
A61K9/1641 (Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds) appears on 2,332 US grants and 3,633 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,332
- Published applications
- 3,633
- Assignees
- 1,388
- Inventors
- 5,941
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 4 | 0 |
| 1983 | 3 | 0 |
| 1984 | 2 | 0 |
| 1985 | 5 | 0 |
| 1986 | 4 | 0 |
| 1987 | 9 | 0 |
| 1988 | 9 | 0 |
| 1989 | 11 | 0 |
| 1990 | 17 | 0 |
| 1991 | 17 | 0 |
| 1992 | 12 | 0 |
| 1993 | 18 | 0 |
| 1994 | 23 | 0 |
| 1995 | 32 | 0 |
| 1996 | 42 | 0 |
| 1997 | 52 | 0 |
| 1998 | 43 | 0 |
| 1999 | 58 | 0 |
| 2000 | 49 | 0 |
| 2001 | 69 | 35 |
| 2002 | 78 | 99 |
| 2003 | 71 | 135 |
| 2004 | 42 | 129 |
| 2005 | 39 | 148 |
| 2006 | 54 | 119 |
| 2007 | 37 | 106 |
| 2008 | 31 | 144 |
| 2009 | 24 | 123 |
| 2010 | 46 | 178 |
| 2011 | 48 | 144 |
| 2012 | 81 | 138 |
| 2013 | 105 | 161 |
| 2014 | 139 | 154 |
| 2015 | 121 | 164 |
| 2016 | 107 | 189 |
| 2017 | 110 | 197 |
| 2018 | 117 | 138 |
| 2019 | 97 | 149 |
| 2020 | 95 | 170 |
| 2021 | 76 | 163 |
| 2022 | 74 | 154 |
| 2023 | 69 | 136 |
| 2024 | 59 | 133 |
| 2025 | 80 | 124 |
| 2026 | 47 | 103 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Formulation to deter abuse of drugs by smoking22 Sep 2026US 12,740,944 B2Purdue Research Foundation
- Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof15 Sep 2026US 12,734,219 B2Peptron, Inc.
- PLGA microparticles, a sustained release formulation thereof and a production method thereof25 Aug 2026US 12,714,673 B2M. Technique Co., Ltd.
- Compositions comprising a tweak ligand and methods of using same25 Aug 2026US 12,714,740 B2Children's Hospital Medical Center
- Cytotoxic lipid particles targeted to tumor-associated myeloid cells (TAMCS) and synergized with radiation therapy for treating glioblastoma25 Aug 2026US 12,714,747 B2Northwestern University
- Drug-containing particle8 Oct 2026US 2026/0306409 A1Towa Pharmaceutical Co., Ltd.
- Cannabidiol formulations1 Oct 2026US 2026/0294812 A1Dsm IP Assets B.V.
- Injectable, sustained-release microsphere formulations containing rapamycin and/or rapamycin analogs and methods of making and using the formulations1 Oct 2026US 2026/0294877 A1Texas Animal Health Innovations LLC
- Injectable, sustained-release microsphere formulations containing rapamycin and/or rapamycin analogs and methods of making and using the formulations1 Oct 2026US 2026/0294878 A1Texas Animal Health Innovations LLC
- Solid dispersion of p2x4 inhibitor, and preparation method therefor and use thereof24 Sep 2026US 2026/0284010 A1Wuhan Createrna Science and Technology Co., Ltd.
Most cited
By later US patents
- Polyhydroxyalkanoate compositions having controlled degradation rates1,516US 6,867,248 B1Metabolix, Inc. · 2005
- Particle immobilized coatings and uses thereof1,386US 8,679,454 B2SurModics, Inc. · 2014
- Method for making a bioerodible material for the sustained release of a medicament and the material made from the method1,033US 5,456,917 ACambridge Scientific, Inc. · 1995
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers896US 5,410,016 ABoard of Regents, The University of Texas System · 1995